<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894556</url>
  </required_header>
  <id_info>
    <org_study_id>0462-087</org_study_id>
    <secondary_id>2009_587</secondary_id>
    <nct_id>NCT00894556</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to provide evidence supporting the benefit of Rizatriptan in patients who have an
      inadequate response to sumatriptan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2009</start_date>
  <completion_date type="Actual">January 12, 2010</completion_date>
  <primary_completion_date type="Actual">January 12, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief (PR)</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Freedom (PF)</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rizatriptan - Rizatriptan - Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rizatriptan - Placebo - Rizatriptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo - Rizatriptan - Rizatriptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline Phase</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sumatriptan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rizatriptan</intervention_name>
    <description>Single dose of 10 mg orally disintegrating tablet at onset of migraine attack</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo to Rizatriptan</description>
    <arm_group_label>Treatment Sequence A</arm_group_label>
    <arm_group_label>Treatment Sequence B</arm_group_label>
    <arm_group_label>Treatment Sequence C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Sumatriptan</intervention_name>
    <description>single dose of generic sumatriptan 100 mg at onset of migraine attack</description>
    <arm_group_label>Baseline Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a history of migraine with or without aura for 1 year or more with 2-8
             moderate or severe migraine attacks per month

          -  Patient generally does not respond to treatment with sumatriptan

          -  Patient of reproductive potential agrees to remain abstinent or use one method of
             highly effective birth control (i.e. IUD, condoms, hormonal contraceptive, diaphragm,
             vasectomy) for the duration of the study

          -  Patient is able to complete paper diary

        Exclusion Criteria:

          -  Patient is pregnant or breast feeding or excepts to become pregnant during the study

          -  Patient has history of mild migraine attacks or migraines that usually resolve
             spontaneously in less than 2 hours

          -  Patient has basilar or hemiplegic migraines

          -  Patient is unable to distinguish between migraine attacks from other types of
             headaches

          -  Patient has more than 15 headache-days per month

          -  Patient was greater than 50 years old at age of migraine onset

          -  Patient has failed to respond to 3 or more triptans

          -  Patient has a repeated history of failing to respond to or tolerate rizatriptan

          -  Patient uses opioids as primary migraine therapy

          -  Patient uses daily opioids

          -  Patient has a history of Cerebrovascular Accident (CVA) or other significant
             cardiovascular disease

          -  Patient has uncontrolled hypertension

          -  Patient has a history of neoplastic disease

          -  Patient is taking a serotonin reuptake inhibitor (SSRI or SNRI) where the dose has
             changed 3 months prior to screening

          -  Patient has a history of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Seeburger JL, Taylor FR, Friedman D, Newman L, Ge Y, Zhang Y, Hustad CM, Lasorda J, Fan X, Hewitt D, Ho T, Connor KM. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011 May;31(7):786-96. doi: 10.1177/0333102410390399. Epub 2010 Nov 15.</citation>
    <PMID>21078681</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2009</study_first_posted>
  <results_first_submitted>September 23, 2010</results_first_submitted>
  <results_first_submitted_qc>December 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2011</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of acute migraine with or without aura in adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 21 study centers in the United States.
First Patient In: 10-Jun-2009;
First Patient Treated: 26-Jun-2009
Last Patient Last Visit: 12-Jan-2010;
Last Patient Treated: 25-Dec-2009</recruitment_details>
      <pre_assignment_details>Participants who met entry criteria but had evidence of suicidality or were severely depressed (based on
questionnaire scores) were excluded. Within 2 months of entry, participants were to treat a moderate/
severe migraine attack with sumatriptan 100 mg and were randomized if they still had moderate or severe
pain at 2 hours post-dose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rizatriptan / Rizatriptan / Placebo</title>
          <description>Each patient was randomized to receive one of 3 treatment sequences. Three qualifying migraines were
then treated based on the prescribed sequence. Two migraine attacks were treated with rizatriptan and one
with placebo.
The first migraine was treated with Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); the second migraine with Rizatriptan 10 mg ODT; the third migraine with placebo.</description>
        </group>
        <group group_id="P2">
          <title>Rizatriptan / Placebo / Rizatriptan</title>
          <description>Each patient was randomized to receive one of 3 treatment sequences. Three qualifying migraines were
then treated based on the prescribed sequence. Two migraine attacks were treated with rizatriptan and one
with placebo.
The first migraine was treated with Rizatriptan 10 mg ODT; the second migraine with placebo; and the third migraine with Rizatriptan 10 mg ODT.</description>
        </group>
        <group group_id="P3">
          <title>Placebo / Rizatriptan / Rizatriptan</title>
          <description>Each patient was randomized to receive one of 3 treatment sequences. Three qualifying migraines were
then treated based on the prescribed sequence. Two migraine attacks were treated with rizatriptan and one
with placebo.
The first migraine was treated with Placebo; the second migraine with Rizatriptan 10mg ODT; and the third migraine with Rizatriptan 10 mg ODT</description>
        </group>
        <group group_id="P4">
          <title>Sumatriptan 100 mg</title>
          <description>Pre-Randomization Phase conducted 2 months prior to Study Randomization. Eligible participants were to treat a moderate/severe migraine attack with sumatriptan 100 mg. Those who failed to respond to sumatriptan (i.e. continued to experience moderate or severe pain at 2 hours post dose) were classified as non-responders and were entered into the double-blind treatment phase of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet Randomization Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37">Participants who were randomized into the treatment phase</participants>
                <participants group_id="P2" count="36">Participants who were randomized into the treatment phase</participants>
                <participants group_id="P3" count="36">Participants who were randomized into the treatment phase</participants>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33">Participants who treated 3 acute migraine attacks with study medication during the treatment phase</participants>
                <participants group_id="P2" count="32">Participants who treated 3 acute migraine attacks with study medication during the treatment phase</participants>
                <participants group_id="P3" count="35">Participants who treated 3 acute migraine attacks with study medication during the treatment phase</participants>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Qualifying Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rizatriptan / Rizatriptan / Placebo</title>
          <description>The first migraine was treated with Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); the second migraine with Rizatriptan 10 mg ODT; the third migraine with placebo.</description>
        </group>
        <group group_id="B2">
          <title>Rizatriptan / Placebo / Rizatriptan</title>
          <description>The first migraine was treated with Rizatriptan 10 mg ODT; the second migraine with placebo; and the third migraine with Rizatriptan 10 mg ODT.</description>
        </group>
        <group group_id="B3">
          <title>Placebo / Rizatriptan / Rizatriptan</title>
          <description>The first migraine was treated with Placebo; the second migraine with Rizatriptan 10mg ODT; and the third migraine with Rizatriptan 10 mg ODT</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="13.4"/>
                    <measurement group_id="B2" value="43.6" spread="8.9"/>
                    <measurement group_id="B3" value="43.5" spread="10.2"/>
                    <measurement group_id="B4" value="43.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief (PR)</title>
        <description>Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>The FAS population included all randomized participants who had at least one evaluable attack. To be considered an evaluable attack the participant must have administered study treatment for this attack and must have had both a baseline severity measurement and at least one post-dose efficacy measurement prior to or including the 2-hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan</title>
            <description>Migraines were treated with Rizatriptan 10 mg ODT.
Although a patient may have appeared twice in the rizatriptan group, the patient was counted only once for the rizatriptan group. It is possible for one patient to be counted in both the rizatriptan and placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Migraines were treated with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PR)</title>
          <description>Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain relief (PR) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 post dose.</description>
          <population>The FAS population included all randomized participants who had at least one evaluable attack. To be considered an evaluable attack the participant must have administered study treatment for this attack and must have had both a baseline severity measurement and at least one post-dose efficacy measurement prior to or including the 2-hour time point.</population>
          <units>attacks</units>
          <param>Number</param>
          <units_analyzed>Evaluable Attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Evaluable Attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Resulting in PR at 2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not resulting in PR at 2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized Linear Mixed Model (GLIMMIX)</method>
            <method_desc>An unstructured covariance matrix was used to model the correlation among repeated measurements within patient.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Freedom (PF)</title>
        <description>Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>The FAS population included all randomized participants who had at least one evaluable attack. To be considered an evaluable attack the participant must have administered study treatment for this attack and must have had both a baseline severity measurement and at least one post-dose efficacy measurement prior to or including the 2-hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan</title>
            <description>Migraines were treated with Rizatriptan 10 mg ODT.
Although a patient may have appeared twice in the rizatriptan group, the patient was counted only once for the rizatriptan group. It is possible for one patient to be counted in both the rizatriptan and placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Migraines were treated with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Freedom (PF)</title>
          <description>Headache pain severity, relative to the administration of study medication, was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild pain), 2 (moderate pain), or 3 (severe pain). Pain freedom (PF) is defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 (no pain) post dose.</description>
          <population>The FAS population included all randomized participants who had at least one evaluable attack. To be considered an evaluable attack the participant must have administered study treatment for this attack and must have had both a baseline severity measurement and at least one post-dose efficacy measurement prior to or including the 2-hour time point.</population>
          <units>attacks</units>
          <param>Number</param>
          <units_analyzed>Evaluable Attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Evaluable Attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Resulting in PF at 2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not resulting in PF at 2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized Linear Mixed Model (GLIMMIX)</method>
            <method_desc>An unstructured covariance matrix was used to model the correlation among repeated measurements within patient.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time that participants were enrolled (signed informed consent) through 14 days after the last dose of study medication.</time_frame>
      <desc>Participants reported adverse events in a paper diary and were collected by the site at Visits 2 and 3, and 14 days after the last dose of study medication. AEs that occurred in the Baseline Phase (prior to randomization) are reported as a separate arm. Events not applicable to a particular Study Phase are reported as (0/0).</desc>
      <group_list>
        <group group_id="E1">
          <title>Rizatriptan 10 mg</title>
          <description>Patients took at least one dose of study medication. It is possible for one patient to be counted twice (once in each treatment group).
Although a patient may have had two or more adverse events of the same type, the patient is counted only once for that type of adverse event.
Adverse events occurring within 14 days of administration of Rizatriptan 10 mg are attributed to Rizatriptan 10 mg group even if placebo was administered more recently.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
        <group group_id="E3">
          <title>Sumatriptan 100 mg</title>
          <description>Adverse Events that occurred in the Baseline Phase (prior to taking study medication) are identified in the tables as &quot;Baseline Phase&quot;</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion Sickness - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid Pain - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vision blurred - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dry mouth - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nausea - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Chest discomfort - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Fatigue - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Oedema peripheral - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pain - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Fatigue - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling of relaxation - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gait disturbance - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Influenza like illness - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sensation of pressure - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Rhinitis - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Facial bones fracture - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Wrist fracture - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Muscle spasms - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Muscle tightness - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Neck pain - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Myokymia - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disorder - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dizziness - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Headache - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Migraine - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Paraesthesia - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Sinus headache - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cognitive disorder - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dizziness - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysgeusia - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Paraesthesia - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinus headache - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Somnolence - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Syncope - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Insomnia - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Insomnia - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Throat tightness - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush - Baseline Phase</sub_title>
                <description>Pre-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hot flush - Treatment Phase</sub_title>
                <description>Post-Randomization reported Adverse Event</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

